Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2004 1
2005 5
2006 8
2007 5
2008 9
2009 13
2010 11
2011 18
2012 12
2013 9
2014 12
2015 8
2016 8
2017 9
2018 13
2019 10
2020 9
2021 9
2022 6
2023 4

Text availability

Article attribute

Article type

Publication date

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group. Roehrborn CG, et al. Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19. Eur Urol. 2010. PMID: 19825505 Clinical Trial.
INTERVENTION: Oral daily tamsulosin, 0.4 mg; dutasteride, 0.5 mg; or a combination of both. MEASUREMENTS: The 4-yr primary end point was time to first AUR or BPH-related surgery. ...RESULTS AND LIMITATIONS: Combination therapy was significantly superior to tamsul …
INTERVENTION: Oral daily tamsulosin, 0.4 mg; dutasteride, 0.5 mg; or a combination of both. MEASUREMENTS: The 4-yr primary end …
Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
Zhou Z, Cui Y, Wu J, Ding R, Cai T, Gao Z. Zhou Z, et al. BMC Urol. 2019 Mar 11;19(1):17. doi: 10.1186/s12894-019-0446-8. BMC Urol. 2019. PMID: 30871552 Free PMC article.
BACKGROUND: We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia (BPH) during a treatment cycle of at least 1 year. ...C …
BACKGROUND: We performed a meta-analysis to confirm the efficacy and safety of the combination of tamsulosin plus dutasteride …
Investigation of Suicidality and Psychological Adverse Events in Patients Treated With Finasteride.
Nguyen DD, Marchese M, Cone EB, Paciotti M, Basaria S, Bhojani N, Trinh QD. Nguyen DD, et al. JAMA Dermatol. 2021 Jan 1;157(1):35-42. doi: 10.1001/jamadermatol.2020.3385. JAMA Dermatol. 2021. PMID: 33175100 Free PMC article.
Extensive sensitivity analyses included stratifying by indication (BPH and alopecia) and age (45 and >45 years); comparing finasteride signals with those of drugs with different mechanisms but used for similar indications (minoxidil for alopecia and tamsulosin hydrochlo …
Extensive sensitivity analyses included stratifying by indication (BPH and alopecia) and age (45 and >45 years); comparing finasteride si …
Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
Duan Y, Grady JJ, Albertsen PC, Helen Wu Z. Duan Y, et al. Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):340-348. doi: 10.1002/pds.4361. Epub 2018 Jan 9. Pharmacoepidemiol Drug Saf. 2018. PMID: 29316005
PURPOSE: Clinicians use tamsulosin, an alpha1-adrenoceptor antagonist, to manage symptomatic benign prostatic hyperplasia (BPH). ...Men taking tamsulosin (n = 253 136) were matched at a 1:1 ratio using propensity-scores to each of 6 comparison cohorts: patients who …
PURPOSE: Clinicians use tamsulosin, an alpha1-adrenoceptor antagonist, to manage symptomatic benign prostatic hyperplasia (BPH). ...M …
Effects of dutasteride and tamsulosin on penile morphology in a rodent model.
da Silva MHA, Costa WS, Sampaio FJB, de Souza DB. da Silva MHA, et al. Int Braz J Urol. 2023 May-Jun;49(3):320-333. doi: 10.1590/S1677-5538.IBJU.2022.0583. Int Braz J Urol. 2023. PMID: 37115177 Free article.
PURPOSE: To evaluate the penile morphology after the isolated and combined administration of dutasteride and tamsulosin in a rodent model. MATERIALS AND METHODS: Forty male rats were assigned into the following groups: Control group (C, receiving distilled water, n= …
PURPOSE: To evaluate the penile morphology after the isolated and combined administration of dutasteride and tamsulosin in a r …
Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia.
Dimitropoulos K, Gravas S. Dimitropoulos K, et al. Ther Adv Urol. 2016 Feb;8(1):19-28. doi: 10.1177/1756287215607419. Ther Adv Urol. 2016. PMID: 26834837 Free PMC article. Review.
Following previous studies on the separate administration of dutasteride and tamsulosin, a fixed-dose combination capsule of tamsulosin 0.4 mg and dutasteride 0.5 mg has been approved and released for clinical use in men with BPH. The present review ai …
Following previous studies on the separate administration of dutasteride and tamsulosin, a fixed-dose combination capsule of …
Development of microemulsion of tamsulosin and dutasteride for benign prostatic hyperplasia therapy.
Ciríaco SL, Carvalho IPS, Alves Terceiro Neto J, de Sousa Lima Neto J, de Oliveira DHB, Cunha APGP, Cavalcante YTD, da Silva DTC, da Silva JA, Mineiro ALBB, de Lima Chagas Moreno Fernandes MZ, Carvalho ALM. Ciríaco SL, et al. Colloids Surf B Biointerfaces. 2020 Jan 1;185:110573. doi: 10.1016/j.colsurfb.2019.110573. Epub 2019 Oct 13. Colloids Surf B Biointerfaces. 2020. PMID: 31675643
This disease is treated with the oral administration of combination therapy comprising alpha-blockers (tamsulosin) and 5alpha-reductase inhibitors (dutasteride). However, these compounds have low bioavailability. ...The objectives of this study were to obtain microe …
This disease is treated with the oral administration of combination therapy comprising alpha-blockers (tamsulosin) and 5alpha-reducta …
Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate.
Miller J, Tarter TH. Miller J, et al. Clin Interv Aging. 2009;4:251-8. doi: 10.2147/cia.s4102. Epub 2009 Jun 9. Clin Interv Aging. 2009. PMID: 19554096 Free PMC article. Review.
Interim results of the ongoing Combination of Avodart and Tamsulosin (CombAt) study have shown combination therapy with the 5alpha-reductase inhibitor dutasteride and the alpha1-adrenergic antagonist tamsulosin offer significant improvements from baseline com …
Interim results of the ongoing Combination of Avodart and Tamsulosin (CombAt) study have shown combination therapy with the 5alpha-re …
Effects of Cytochrome P450 and Transporter Polymorphisms on the Bioavailability and Safety of Dutasteride and Tamsulosin.
Villapalos-García G, Zubiaur P, Navares-Gómez M, Saiz-Rodríguez M, Mejía-Abril G, Martín-Vílchez S, Román M, Ochoa D, Abad-Santos F. Villapalos-García G, et al. Front Pharmacol. 2021 Oct 7;12:718281. doi: 10.3389/fphar.2021.718281. eCollection 2021. Front Pharmacol. 2021. PMID: 34690761 Free PMC article.
Dutasteride and tamsulosin are one of the first-line combination therapies for the management of benign prostatic hyperplasia (BPH). ...Furthermore, to date, no pharmacogenetic information is available for dutasteride. Henceforth, we studied the pharmacokinet …
Dutasteride and tamsulosin are one of the first-line combination therapies for the management of benign prostatic hyperplasia …
Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study).
Yamanishi T, Asakura H, Seki N, Tokunaga S. Yamanishi T, et al. Int J Urol. 2017 Jul;24(7):525-531. doi: 10.1111/iju.13359. Epub 2017 May 2. Int J Urol. 2017. PMID: 28466585 Clinical Trial.
METHODS: A total of 163 patients presenting an enlarged prostate (volume >30 mL) and persistent overactive bladder symptoms despite at least 8 weeks of tamsulosin were randomized to receive tamsulosin and dutasteride, or tamsulosin, dutasteride …
METHODS: A total of 163 patients presenting an enlarged prostate (volume >30 mL) and persistent overactive bladder symptoms despite at le …
160 results